JAZZ Initiates Coverage On Citigroup -- Price Target Set at $325

gurufocus.com · 2026-09-30

Jazz Pharmaceuticals Receives New "Buy" Rating from Citigroup On October 24, 2023, Jazz Pharmaceuticals (JAZZ) received a new "Buy" rating from Citigroup. An

TickrTrends take: JAZZ has received analyst coverage initiation from Citigroup with a price target of $325, which provides an external valuation benchmark for investors to assess against the current market price. Given TickrTrends' assessment that JAZZ is fairly valued, this new price target represents a specific milestone that valuation-focused investors should monitor to determine if it signals potential upside or reflects consensus expectations already embedded in the stock's price. In the Healthcare sector context, this coverage initiation adds to the analyst visibility on the company and could influence how the market reprices the stock relative to its fundamental value.

Read the full story at gurufocus.com →